These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22988882)

  • 1. Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.
    Zhao J; Hermanson SB; Carlson CB; Riddle SM; Vogel KW; Bi K; Nichols RJ
    Biochem Soc Trans; 2012 Oct; 40(5):1158-62. PubMed ID: 22988882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
    Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
    J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.
    Ito G; Fujimoto T; Kamikawaji S; Kuwahara T; Iwatsubo T
    PLoS One; 2014; 9(5):e97988. PubMed ID: 24836358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
    Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
    J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
    Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K
    PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of LRRK2: from kinase to substrate.
    Lobbestael E; Baekelandt V; Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.
    Dzamko N; Inesta-Vaquera F; Zhang J; Xie C; Cai H; Arthur S; Tan L; Choi H; Gray N; Cohen P; Pedrioli P; Clark K; Alessi DR
    PLoS One; 2012; 7(6):e39132. PubMed ID: 22723946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
    Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
    Dzamko N; Deak M; Hentati F; Reith AD; Prescott AR; Alessi DR; Nichols RJ
    Biochem J; 2010 Sep; 430(3):405-13. PubMed ID: 20659021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.
    Lobbestael E; Zhao J; Rudenko IN; Beylina A; Gao F; Wetter J; Beullens M; Bollen M; Cookson MR; Baekelandt V; Nichols RJ; Taymans JM
    Biochem J; 2013 Nov; 456(1):119-28. PubMed ID: 23937259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triazolopyridazine LRRK2 kinase inhibitors.
    Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
    Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 14-3-3 proteins are promising LRRK2 interactors.
    Rudenko IN; Cookson MR
    Biochem J; 2010 Sep; 430(3):e5-6. PubMed ID: 20795948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.
    Nichols RJ; Dzamko N; Morrice NA; Campbell DG; Deak M; Ordureau A; Macartney T; Tong Y; Shen J; Prescott AR; Alessi DR
    Biochem J; 2010 Sep; 430(3):393-404. PubMed ID: 20642453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
    Deng X; Dzamko N; Prescott A; Davies P; Liu Q; Yang Q; Lee JD; Patricelli MP; Nomanbhoy TK; Alessi DR; Gray NS
    Nat Chem Biol; 2011 Apr; 7(4):203-5. PubMed ID: 21378983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel cinnoline-based inhibitors of LRRK2 kinase activity.
    Garofalo AW; Adler M; Aubele DL; Bowers S; Franzini M; Goldbach E; Lorentzen C; Neitz RJ; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong AP; Ye XM; Ren Z
    Bioorg Med Chem Lett; 2013 Jan; 23(1):71-4. PubMed ID: 23219325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
    Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
    J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
    Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
    Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.